Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Devices

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Revenue projections:

Revenue projections for PODD
Revenue projections for PODD

PODD's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 2.814000
forwardPE 21.662453
debtToEquity 66.176000
earningsGrowth 0.039000
revenueGrowth 0.312000
grossMargins 0.716330
operatingMargins 0.186650
trailingEps 3.480000
forwardEps 8.080340

PODD's current ratio, being 2.814, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, PODD is well-equipped to meet its immediate financial obligations without any difficulties.
PODD's Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
PODD's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that PODD is projected to improve its financial performance compared to the previous year.

Price projections:

Price projections for PODD
Price projections for PODD

The current valuation of PODD, concerning its projections, presents no apparent risks or opportunities. This neutral outlook may lead investors to adopt a cautious approach as they await further insights into the company's performance.

Insider Transactions:

Insider Transactions for PODD
Insider Transactions for PODD


PODD stock was sold in 9 transactions, with market price at 310.14888848198785.2 separate transactions to buy Insulet Corporation were completed, while market price hovered around 276.30499267578125.Insider transactions show no notable pattern, making it difficult to discern whether these actions signal positive or negative developments within the company.

Recommendation changes over time:

Recommendations trend for PODD
Recommendations trend for PODD


Analysts have maintained a buy bias for PODD, which could prompt investors to consider the stock as a viable investment. With this positive outlook, PODD is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.